Target, indication, mechanism
Plus any internal data you can share under NDA. Public data alone is sufficient to start.
Asset evaluation
Probability of success before Phase II
Today, go/no-go decisions on oncology programs rest on basic research and cell-line validation. We add what those cannot provide: patient molecular data, read before clinical efficacy data exist.
Current state
Decisions made on the wrong model
Investment and termination decisions are made on evidence from systems that do not contain a patient. The first patient-level readout arrives years and tens of millions of dollars later.
One minute
The evaluation path, step by step
Translatability of cell-line models, clinical data for similar drugs, monotherapy activity, commercial opportunity. Each step ends in a recommendation or a conclusive experiment.
Our platform
Investability of oncology programs
Our asset evaluation platform quantifies the probability that a program succeeds, using patient molecular data to anticipate clinical outcomes.
In retrospective validation the model predicts clinical trial outcomes from patient molecular data with 90% accuracy. Methodology and cohort details are available on request.
Sample reports
Two full target evaluation reports, public and free to read. The format is the same as a commissioned evaluation.
Engagement
What an evaluation delivers
Target evaluation report
Dependency evidence by tissue, co-dependencies, resistance mechanisms, patient population size and a translational-risk score. Format as in the samples above.
Weeks, not quarters
From scoping call to written report. Portfolio-wide reviews are scoped separately.